PRURITIS– chronic itch


Dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. (abst – 2002)                                   


Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease.                                                      (abst – 2002) 


The cannabinoid agonist WIN 55, 212-2 increases nociception threshold in cholestatic rats: implications for the treatment of the pruritus of cholestasis.                                                      (abst – 2003)


Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin.     (abst – 2003)             


Pathogenesis and treatment of pruritus in patients with cholestasis              (abst – 2003)


Treatment of the Pruritus of Cholestasis.                (abst – 2004)


Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study.

(abst – 2005)         


Rational symptomatic therapy for chronic pruritus               (abst – 2005)


Old drugs in new role: relieving chronic pruritus; Cannabinoid agonists, opioid receptor antagonists have attracted the attention of dermatologists                                                          (news – 2005)



Cream with endocannabinoids effective in the treatment of pruritus                   (news – 2005)


Cream with endocannabinoids effective in the treatment of pruritus due to kidney disease (news – 2005)                        


Neurophysiological, Neuroimmunological, and Neuroendocrine Basis of Pruritus (full – 2006)                          


Frontiers in pruritus research: scratching the brain for more effective itch therapy (full – 2006)[abstract_text]=&search[article_text]=cannabinoid&search[a   uthors_text]=&search[fpage]=&search[title_text]=&search[volume]=


Topical cannabinoid agonists : An effective new possibility for treating chronic pruritus. (abst – 2006)                      









Adjuvant treatment of atopic eczema: assessment of an emollient containing N- palmitoylethanolamine (ATOPA study).                                                                      (abst – 2008)


Chronic pruritus: targets, mechanisms and future therapies.              (abst – 2008)   nel.Pubmed_RVDocSum&ordinalpos=51


The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities (full – 2009)


Endocannabinoid modulation of scratching response in an acute allergenic model: a new prospective neural therapeutic target for pruritus.                                               (full – 2009)


Cannabinoid system in the skin – a possible target for future therapies in dermatology. (full – 2009)                        


Cannabis: Potential treatment for skin disorders?               (news – 2009)


The Management of Chronic Pruritus in the Elderly                (full – 2010)


Is there a legitimate role for the therapeutic use of cannabinoids for symptom management in chronic kidney disease?                                                                (abst – 2011)


CB1 receptors mediate rimonabant-induced pruritic responses in mice: investigation of locus of action.   (abst – 2011) abant_induced_pruritic_responses_in_mice:_investigation_of_locus_of_action_


Endocannabinoid signaling and epidermal differentiation.               (abst – 2011)


Discovery of S-444823, a potent CB1/CB2 dual agonist as an antipruritic agent. (abst – 2012)                          


Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma.                                                                       (abst – 2012)

Share a link for